Lava Therapeutics Nv (LVTX) SEC Filing 6-K Foreign Issuer Report for the period ending Tuesday, May 17, 2022

Lava Therapeutics Nv

CIK: 1840748 Ticker: LVTX

View differences made from one to another to evaluate Lava Therapeutics Nv's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 6-K Foreign Issuer Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Lava Therapeutics Nv.


Assess how Lava Therapeutics Nv's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Lava Therapeutics Nv's Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Material Contracts, Statements, Certifications & more

Lava Therapeutics Nv provided additional information to their SEC Filing as exhibits

Ticker: LVTX
CIK: 1840748
Form Type: 6-K Foreign Issuer Report
Accession Number: 0001558370-22-009104
Submitted to the SEC: Tue May 17 2022 4:08:47 PM EST
Accepted by the SEC: Tue May 17 2022
Period: Tuesday, May 17, 2022
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: